
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx Inc has demonstrated significant progress in clinical drug development and commercialization of its RenovoCath platform, anticipating a substantial increase in revenue to $1.3 million in 2025 and $4.5 million in 2026. The expansion of active commercial cancer centers from five to nine, including esteemed institutions like City of Hope and Moffitt Cancer Center, underscores the growing adoption of its targeted therapies. Additionally, positive clinical outcomes, marked by a six-month improvement in median overall survival and a 65% reduction in side effects, further enhance the company’s prospects in addressing unmet medical needs in cancer treatment.
Bears say
RenovoRx Inc., a clinical-stage biopharmaceutical company, faces significant financial challenges as evidenced by its revenue of only $0.3 million and a net loss of $2.9 million for the reporting period. The company's focus on developing therapies for cancers with dire prognoses, such as pancreatic cancer—which has a five-year survival rate of just 12%—contributes to the uncertainty surrounding its market potential. Furthermore, despite the presence of growth prospects and an innovative therapeutic platform, the overall concerns regarding its financial health and high-risk profile overshadow any potential rewards, leading to a negative outlook.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares